Last reviewed · How we verify
Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
Approved treatments
- Disitamab vedotin · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma treatment landscape brief
- Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma treatment updates RSS
Frequently asked questions about Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
What drugs treat Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma?
Tracked treatments include Disitamab vedotin.
What is the treatment for Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma?
Standard treatment for Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma includes Disitamab vedotin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma patent cliff · Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma CI report
- Treatment: Disitamab vedotin · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing